FDA clears Zanvastro (zilganersen) as the first disease-modifying therapy for Alexander disease following positive Phase 1-3 trial results.
Mounjaro approval expanded to reduce the risk of major cardiovascular events; The American Academy of Pediatrics has issued updated recommendations for RSV immunization; BTK inhibitor shows promise in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results